For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and ...

For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and he ...

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

A new study shows that long-read sequencing has the potential to improve the rate of diagnosis while reducing the time to diagnosis from years to days -- in a single test and at a much lower cost.

The American Gastroenterology Association (AGA) issued a new clinical guideline recommending antiviral drugs for patients at ...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”) ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...

Cellular senescence, where cells permanently stop dividing, plays a complex role in liver health. In a recent review article, ...

FLC is a rare liver cancer with unique genetic traits, often misdiagnosed until advanced. New research and a clinical trial ...

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC ... But new insights about the disease, coupled with a ...